Milbactor 4 mg/10 mg Film-coated Tablets for Small Cats and Kittens Weighing at Least 0.5 kg

It is recommended to treat all the animals living in the same household
concomitantly.
In order to develop an effective worm control programme local epidemiological
information and the risk of exposure of the cat should be taken into account.
When D. caninum infection is present, concomitant treatment against intermediate
hosts, such as fleas and lice, should be considered to prevent re-infection.
Parasite resistance to any particular class of anthelmintic may develop following
frequent, repeated use of an anthelmintic of that class.

Special precautions for use in animals
No studies have been performed with severely debilitated cats or individuals with
seriously compromised kidney or liver function. The product is not recommended for
such animals or only according to a benefit/risk assessment by the responsible
veterinarian.
Ensure cats and kittens weighing between 0.5 kg and ≤2 kg receive the appropriate
tablet strength (4 mg milbemycin oxime/10 mg praziquantel) and the appropriate
dose (1/2 or 1 tablet) for the corresponding weight band (1/2 tablet for cats weighing
0.5 to 1 kg; 1 tablet for cats weighing >1 to 2 kg).
Special precautions to be taken by the person administering the veterinary medicinal
product to animals
People with known hypersensitivity to the active substances or the excipients should
avoid contact with the veterinary medicinal product.
In the event of accidental ingestion of the tablets, particularly by a child, seek medical
advice immediately and show the package leaflet or the label to the doctor.
Wash hands after use.
Other precautions
Echinococcosis represents a hazard for humans. As Echinococcosis is a notifiable
disease to the World Organisation for Animal Health (OIE), specific guidelines on the
treatment and follow-up, and on the safeguard of persons, need to be obtained from
the relevant competent authority.

Revised: July 2021
AN: 02341/2020 & 02342/2020Page 3 of 6